Pseudomyxoma peritonei (PMP) is a rare disorder characterized by the accumulation of mucous fluid (mucous exudate) in the peritoneal cavity as a result of leakage of mucus-forming cell secretion, most often from a tumor located in the appendix or ovaries. This condition can arise as a result of, as a rule, mucinous adenocarcinoma, which differs from ordinary adenocarcinoma by the presence of a significant amount of mucous production. PMP is often associated with progressive dyspnea, abdominal pain and abdominal distension. The pathology has a peculiar manifestation, which often leads to difficulties in diagnosis and timely therapy.
History of the disease and interesting historical facts
The history of pseudomyxoma peritonei goes back to the 19th century, when the first description of this condition appeared in the works of radical surgeons. Given the rarity of the disease, many facts may have remained unnoticed for a long time. An important moment in the history of the study of PMP was the discovery of the connection between mucinous tumors, such as mucinous adenocarcinoma, and this disease. One of the interesting historical facts is that the first cases of pseudomyxoma peritonei were documented as a complication of appendicitis. Over the years, this disease has attracted the attention of researchers who have begun to study in detail the cellular and molecular mechanisms responsible for its development. Also, over time, information has accumulated on diagnostic methods and approaches to treatment.
Epidemiology
According to various studies, pseudomyxoma peritonei occurs in 1-2% cases of all abdominal tumors. The disease usually occurs in people aged 30-60 years, with some predominant interest in the female sex. Various sources note that the frequency of occurrence may vary depending on the geographic region and ethnicity of the population. For example, in some countries, this diagnosis is made less frequently due to a lack of clinical data or the peculiarities of local oncological practice. Most often, PMP occurs due to the proliferation of mucinous tumors, and early detection and diagnosis of this condition is extremely important for timely intervention.
Genetic predisposition to this disease
To date, it has been established that some genetic factors may contribute to the development of pseudomyxoma peritonei, although this is not yet known enough. Studies show that mutations in oncology-related genes, such as KRAS, TP53 and others, may play an important role in the pathogenesis of this disease. Detection of such changes may indicate the development of mucinous tumors, which become the source of pseudomyxoma. Institutes of genetic predisposition to tumor diseases are also suspected, but further research and case analysis are needed for a more detailed understanding of the inheritance mechanism.
Risk factors for the development of this disease
There are various risk factors that contribute to the occurrence of pseudomyxoma peritonei and the development of mucinous tumors. The main ones include:
- The presence of benign or malignant neoplasms in the abdominal organs.
- Chronic inflammation of the abdominal organs, in particular appendicitis.
- Previous surgical interventions in the abdominal area, which can provoke cell metastasis.
- Environment - exposure to carcinogenic chemicals.
- Genetic predisposition to diseases associated with tumor formation.
- Some infections, especially viral ones, such as human papillomavirus (HPV).
Understanding these factors allows physicians to better monitor patients and recommend procedures to prevent them.
Diagnosis of this disease
Diagnosis of pseudomyxoma peritonei is quite challenging because symptoms may be non-specific and may mimic other conditions. Key symptoms may include:
- Abdominal pain or discomfort.
- Abdominal enlargement or ascites.
- Digestive problems, including nausea and vomiting.
- Increase in body weight due to accumulation of exudate.
- Decreased appetite and weight loss.
Laboratory tests often include a complete blood count, biochemical markers to determine inflammation and possible tumor markers. Radiological examinations such as ultrasound, CT and MRI play an important role in visualizing and evaluating the abdominal cavity. Their use allows to detect fluid accumulation and the presence of tumors. Differential diagnosis is necessary to exclude other diseases such as ovarian cancer, carcinomatosis and other conditions.
Treatment
Treatment of pseudomyxoma peritonei should be multidisciplinary and include both surgical and conservative approaches. Common approaches include:
- Surgical intervention - resection of the primary tumor and removal of mucinous exudate.
- Pharmacological treatment - the use of chemotherapy to control growth and metastasis.
- Supportive care – management of symptoms such as pain and ascites.
- Installation of drainage systems to remove excess fluid.
Surgery is often the only radical option, but its appropriateness is determined by the stage of the disease. Pharmacological treatment may include the use of chemotherapeutic agents or immunotherapy, but their effectiveness in this context requires further study.
List of medications used to treat this disease
Some of the commonly used medications include:
- Cisplatin.
- Paclitaxel.
- Doxorubicin.
- Folex.
- Pemetrexed.
These drugs can be used in various treatment regimens depending on the stage and clinical characteristics of the disease.
Disease monitoring
Disease monitoring includes regular examinations and tests. The prognosis in most cases depends on the stage of the disease at the time of diagnosis. Complications may include functional disorders of the abdominal organs, invasive complications or progressive metastasis. An important point in the management of patients with PMB is active monitoring of the dynamics of exudate and possible relapse.
Age-related features of the disease
Pseudomyxoma peritonei exhibits different characteristics depending on age group. In young people, the condition is more often associated with late-stage mucinous tumors, while older patients may have more pronounced systemic manifestations. PMP is rare in children, suggesting the need for further study of genetic and environmental factors in its occurrence.
Questions and Answers
- What are the main symptoms of pseudomyxoma peritonei? The main symptoms include abdominal distension, abdominal pain, ascites, digestive problems and weight loss.
- How is this disease diagnosed? Diagnostics includes laboratory tests, radiological examinations and differential diagnosis with other pathologies.
- What is the treatment for pseudomyxoma peritonei? Treatment may be surgical, pharmacological, and supportive, including drainage of fluid from the abdominal cavity.
- What is the role of genetics in the development of pseudomyxoma peritonei? Genetic mutations such as KRAS and TP53 may predispose to the development of mucinous tumors and, consequently, PMB.
- What is the prognosis for pseudomyxoma peritonei? The prognosis depends on the stage of the disease at the time of diagnosis and can vary from favorable to unfavorable depending on the presence of metastasis.
